ClinicalTrials.gg
RecruitingNCT07123038Updated Apr 16, 2026

A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic

An observational study in Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS), sponsored by Sonoma Biotherapeutics, Inc.. Recruiting at 10 sites in United States. Open to participants aged 18 Years to 71 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Sonoma Biotherapeutics, Inc. · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
36
Ages
18 Years to 71 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 121 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Planned enrollment
170th of 199
36 · median 200
Started
2025
with 30 others
Observational
201 of 975
29 open now
Primary completion
2040-12
later than 117 of 120 live
Registered
942nd of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 170th largest by planned enrollment of the 199 observational ones that give a count, is one of 31 that started in 2025, is one of 201 observational ones, reaches primary completion later than 117 of the 120 other live ones, and was the 942nd registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 71 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.

Read the detailed description

The purpose of this LTFU study is to evaluate safety (delayed adverse events) for up to 15 years in subjects who have received a gene-modified Treg therapeutic within clinical studies NCT06201416, NCT6361836. This is a Phase 4, multi-center long-term follow-up observational study to evaluate long-term safety in subjects who have received a gene-modified Treg therapeutic across Sonoma Biotherapeutics, Inc. clinical studies. The duration of the study is up to 15 years after dose of a Treg therapeutic in prior parent treatment protocols (SBT777101-01 and SBT777101-02) conducted by the Sponsor. Study visits will occur in accordance with the Schedule of Assessments.

03

Conditions studied

  • Rheumatoid Arthritis (RA)
  • Hidradenitis Suppurativa (HS)

Keywords

  • Rheumatoid Arthritis
  • Long Term Follow Up Study
  • Treg
  • SBT0000-01
  • Hidradenitis Suppurativa
  • SBT777101
  • SBT777101-01
  • SBT777101-02
04

Who can participate

Ages eligible
18 Years to 71 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Enrolled participants will be determined by the number of subjects participating in the SBT777101-01 and SBT777101-02 studies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject was previously administered at least 1 dose of a Sonoma Biotherapeutics, Inc. gene-modified Treg therapeutic in a prior parent treatment protocol.
  • Subject understands the purpose and risks of the study and is willing to provide written .
  • Subject is willing to comply with all study procedures for the follow-up period.

Exclusion criteria

Exclusion Criteria:

  • Participation in the study is not in the subject's best interest, in the opinion of the Investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
36 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Participants exposed to SBT777101 Treg cell therapy

    Participants exposed to SBT777101 during the original Phase 1 clinical safety study (NCT06201416, NCT06361836)

    Other: Long Term Safety Monitoring Procedures

Interventions

  • OtherLong Term Safety Monitoring Procedures

    In accordance with the schedule of assessments, participants will complete the long term safety and health questionnaire and will undergo routine physical examinations. A review will be conducted on selected adverse events, medical history, and concomitant medication use. Collection of biospecimens (blood and tissue) will be taken as appropriate at scheduled visits to monitor for delayed adverse events related to prior cell therapy.

06

What researchers measure

Primary outcomes

  1. Incidence of delayed adverse events considered at least possibly related to the SBT777101 gene-modified Treg therapeutic

    Time frame: 15 years

Secondary outcomes

  1. Persistence of the SBT777101 gene-modified Treg therapeutic

    Time frame: 15 years

  2. Incidence of replication competent lentivirus (RCL)

    Time frame: 15 years

  3. Mortality in patients who received a gene-modified Treg therapeutic

    Time frame: 15 years

07

Study locations

7 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2040, 185 months after the start.

Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 113. This study's planned 185 months is above that.

Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2025
First posted
Aug 14, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Dec 2040
CompletionEst.
Dec 2040
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07123038
Lead sponsor
Sonoma Biotherapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Jul 22, 2025
Primary completion
Dec 2040 (estimated)
Completion
Dec 2040 (estimated)
Last update
Apr 16, 2026

Study contacts

Sabrina Fox-Bosetti, MPH
Contact
clinicaloperations@sonomabio.com
415-992-6245
Jason Do
Contact
clinicaloperations@sonomabio.com
415-992-6245
Sarah Baxter, MD, PhD
study director · Sonoma Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion